Nasonex (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal cells, suppressing the release of inflammatory cytokines and limiting the infiltration of immune cells. This reduces swelling, mucus production, and vascular leakage, leading to improved nasal airflow and symptom control.

The prescribed dose of Nasonex is determined by the treating physician based on the patient’s age, severity of symptoms, and clinical response. The prescriber will provide specific instructions on the number of sprays per nostril and the frequency of administration.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nasonex.

To request Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasonex (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency agents such as fluticasone, mometasone may achieve symptom control at similar or lower spray volumes, but choice of therapy depends on individual response and physician preference.

Nasonex should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and discard any product that appears discolored or contaminated.

Nasonex is a metered‑dose nasal spray. After gently shaking the bottle, the user tilts the head slightly forward, inserts the nozzle into one nostril, closes the opposite nostril, and sprays the prescribed number of actuations while breathing in gently. The process is then repeated for the other nostril if directed.

Serious risks, though uncommon, include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes, or systemic symptoms.

Nasonex is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections or recent nasal surgery unless directed by a physician.